ផ្សាយផ្ទាល់ព័ត៌មានថ្មីៗទូទាំងពិភពលោកទាក់ទងនឹង Bitcoin, Ethereum, Crypto, Blockchain បច្ចេកវិទ្យាសេដ្ឋកិច្ច។ ធ្វើបច្ចុប្បន្នភាពរៀងរាល់នាទី។ មានគ្រប់ភាសា។
ទំហំអក្សរ Photograph by Georges Gobet/AFP/Getty Images ការព្យាបាលចំណុចរបត់ stock has more than doubled after Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the latest deal for a beaten-up biotech stock.Turning Point stock (TPTX) was up 114% to $73.26 at 7:05 a.m. Friday after Bristol (BMY) said that it would purchase the small-cap biotech company for $76 a share. Bristol stock is little changed. Turning Point has no current products for sale, but does have a lung cancer drug in clinical trials, and is working on other cancer treatments. Apparently, Bristol feels good enough about these treatments—and the technology behind them—to pay up for the company.“The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset,” Bristol CEO Giovanni Caforio បាននិយាយនៅក្នុងសេចក្តីថ្លែងការណ៍មួយ. “With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.”more m&a news Kohl’s Offers Show Scars of the Retail RoutThe deal is just the latest in the biotech space. Pfizer (PFE) announced ការទិញ of Biohaven (BHVN) for $11 billion on May 10, while ក្រុមហ៊ុន GlaxoSmithKline (GSK) said it would buy សៀរ៉ា ជំងឺមហារីក (SRRA) for $1.9 billion in April. “BMY/TPTX brings the Biotech public-for-public M&A count to 7 YTD and $21.3B in dollar value, so we’re annualizing to 17 takeouts and $50.7B in dollar value for 2022 which is below 2021’s 17 takeouts for $61B in dollar value,” writes Jefferies’ Will Sevush.And those numbers are still too small to be of much help to biotech stocks. the អេសឌីអេសអេសភីភីជីអ៊ីធីជីធីអេហ្វ (XBI) has dropped 39% this year, and is up just 0.4% over the past week even as the SPDR S&P 500 ETF (SPY) has gained 3%. Turning Point stock had dropped 28% through Thursday’s close. Bristol Myers គឺជា របស់បារុន ការជ្រើសរើសភាគហ៊ុន on May 26, in part for a pipeline that includes more than 10 potential cancer treatments. Now it has another.សរសេរទៅបិនលេវីសនៅ [អ៊ីមែលការពារ]
ការព្យាបាលចំណុចរបត់ stock has more than doubled after
Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the latest deal for a beaten-up biotech stock.
Turning Point stock (TPTX) was up 114% to $73.26 at 7:05 a.m. Friday after Bristol (BMY) said that it would purchase the small-cap biotech company for $76 a share. Bristol stock is little changed.
Turning Point has no current products for sale, but does have a lung cancer drug in clinical trials, and is working on other cancer treatments. Apparently, Bristol feels good enough about these treatments—and the technology behind them—to pay up for the company.
“The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset,” Bristol CEO Giovanni Caforio បាននិយាយនៅក្នុងសេចក្តីថ្លែងការណ៍មួយ. “With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.”
The deal is just the latest in the biotech space.
Pfizer (PFE) announced ការទិញ of Biohaven (BHVN) for $11 billion on May 10, while
ក្រុមហ៊ុន GlaxoSmithKline (GSK) said it would buy
សៀរ៉ា ជំងឺមហារីក (SRRA) for $1.9 billion in April. “BMY/TPTX brings the Biotech public-for-public M&A count to 7 YTD and $21.3B in dollar value, so we’re annualizing to 17 takeouts and $50.7B in dollar value for 2022 which is below 2021’s 17 takeouts for $61B in dollar value,” writes Jefferies’ Will Sevush.
And those numbers are still too small to be of much help to biotech stocks. the
អេសឌីអេសអេសភីភីជីអ៊ីធីជីធីអេហ្វ (XBI) has dropped 39% this year, and is up just 0.4% over the past week even as the
SPDR S&P 500 ETF (SPY) has gained 3%. Turning Point stock had dropped 28% through Thursday’s close.
Bristol Myers គឺជា របស់បារុន ការជ្រើសរើសភាគហ៊ុន on May 26, in part for a pipeline that includes more than 10 potential cancer treatments. Now it has another.
សរសេរទៅបិនលេវីសនៅ [អ៊ីមែលការពារ]
Source: https://www.barrons.com/articles/turning-point-stock-bristol-myers-deal-51654255880?siteid=yhoof2&yptr=yahoo